BAX / BCL2  RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia | Zendy

Sharawat Surender Kumar | Zendy; Bakhshi Radhika | Zendy; Vishnubhatla Sreenivas | Zendy; Gupta Ritu | Zendy; Bakhshi Sameer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

BAX / BCL2 RMFI ratio predicts better induction response in pediatric patients with acute myeloid leukemia

Author(s) -

Sharawat Surender Kumar,

Bakhshi Radhika,

Vishnubhatla Sreenivas,

Gupta Ritu,

Bakhshi Sameer

Publication year - 2013

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.24518

Subject(s) - medicine , taqman , flow cytometry , myeloid leukemia , leukemia , gastroenterology , myeloid , cytogenetics , real time polymerase chain reaction , microbiology and biotechnology , immunology , gene , biology , genetics , chromosome

BAX / BCL2 ratio in pediatric AML has not been evaluated. In this first prospective study, we evaluated BAX / BCL2 transcript and RMFI ratio in 64 patients using real‐time PCR (TaqMan Probe chemistry) and flow‐cytometry, respectively. There was no correlation of BAX / BCL2 transcript ratio with RMFI ratio (R = −0.05; P = 0.715). Patients with WBC count >50,000/mm 3 had lower BAX / BCL2 RMFI ratio ( P = 0.043), whereas no difference in ratio was observed among patients of different cytogenetics subgroups ( P = 0.786). Higher BAX / BCL2 RMFI ratio was associated positively with CR rate ( P = 0.03), but this study was unable to show that it translated into improved EFS or OS. Pediatr Blood Cancer 2013;60E63‐E66. © 2013 Wiley Periodicals, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research